Patents by Inventor Patrick Rheault

Patrick Rheault has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VACCINE
    Publication number: 20170290905
    Abstract: The present invention relates to Human Rhinovirus (HRV) Virus-Like Particles (VLPs) and methods of making HRV VLPs.
    Type: Application
    Filed: September 17, 2015
    Publication date: October 12, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Cindy CASTADO, Steve LABBE, Patrick RHEAULT
  • Recombinant RSV vaccines
    Patent number: 9492531
    Abstract: This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: November 15, 2016
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Guy Jean Marie Fernand Pierre Baudoux, Normand Blais, Sonya L. Cyr, Patrick Rheault, Jean-Louis Ruelle
  • STREPTOCOCCUS PYOGENES ANTIGENS AND CORRESPONDING DNA FRAGMENTS
    Publication number: 20160326221
    Abstract: The present invention relates to antigens more particularly antigens of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.
    Type: Application
    Filed: April 14, 2016
    Publication date: November 10, 2016
    Inventors: Denis Martin, Bernard R. Brodeur, Josee Hamel, Stephane Rioux, Patrick Rheault
  • Streptococcus pyogenes antigens and corresponding DNA fragments
    Patent number: 9340586
    Abstract: The present invention relates to antigens more particularly antigens of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: May 17, 2016
    Assignee: ID BIOMEDICAL CORPORATION OF QUEBEC
    Inventors: Denis Martin, Bernard R. Brodeur, Josee Hamel, Stephane Rioux, Patrick Rheault
  • RECOMBINANT RSV ANTIGENS
    Publication number: 20160122398
    Abstract: This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: January 8, 2016
    Publication date: May 5, 2016
    Inventors: Guy Jean Marie Fernand Pierre Baudoux, Jean-Louis Ruelle, Normand Blais, Patrick Rheault
  • RECOMBINANT RSV ANTIGENS
    Publication number: 20150166610
    Abstract: This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: October 14, 2013
    Publication date: June 18, 2015
    Inventors: Guy Jean Marie Fernand Pierre BAUDOUX, Jean-Louis Ruelle, Normand Blais, Patrick Rheault
  • STREPTOCOCCUS PYOGENES ANTIGENS AND CORRESPONDING DNA FRAGMENTS
    Publication number: 20150017684
    Abstract: The present invention relates to antigens more particularly antigens of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.
    Type: Application
    Filed: July 31, 2014
    Publication date: January 15, 2015
    Inventors: Denis Martin, Bernard R. Brodeur, Josee Hamel, Stephane Rioux, Patrick Rheault
  • Vaccine
    Patent number: 8889146
    Abstract: The present disclosure provides immunogenic compositions that include at least two paramyxovirus F protein antigens selected from human metapnuemovirus (hMPV), paarainfluenza virus (PIV) and respiratory syncytial virus (RSV). The antigens of the disclosed compositions are recombinant F protein polypeptides, which have been modified to stabilize the trimeric prefusion conformation. Nucleic acids encoding the antigens, as well as methods for their production and use are also provided.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: November 18, 2014
    Assignee: GlaxoSmithKline Biologicals, SA
    Inventors: Ventzislav B. Vassilev, Virginie Van Scherpenzeel Thim, Normand Blais, Patrick Rheault
  • antigens and corresponding DNA fragments
    Patent number: 8821895
    Abstract: The present invention relates to antigens, more particularly antigenS of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: September 2, 2014
    Assignee: ID Biomedical Corporation of Quebec
    Inventors: Denis Martin, Bernard R. Brodeur, Josee Hamel, Stephane Rioux, Patrick Rheault
  • Recombinant RSV antigens
    Patent number: 8563002
    Abstract: This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: October 22, 2013
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Guy Jean Marie Fernand Pierre Baudoux, Normand Blais, Patrick Rheault, Jean-Louis Ruelle
  • antigens and corresponding DNA fragments
    Patent number: 8298551
    Abstract: The present invention relates to antigens, more particularly antigens of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.
    Type: Grant
    Filed: September 28, 2009
    Date of Patent: October 30, 2012
    Assignee: ID Biomedical Corporation of Quebec
    Inventors: Denis Martin, Bernard R. Brodeur, Josee Hamel, Stephane Rioux, Patrick Rheault
  • VACCINE
    Publication number: 20120135028
    Abstract: The present disclosure provides immunogenic compositions that include at least two paramyxovirus F protein antigens selected from human metapnuemovirus (hMPV), paarainfluenza virus (PIV) and respiratory syncytial virus (RSV). The antigens of the disclosed compositions are recombinant F protein polypeptides, which have been modified to stabilize the trimeric prefusion conformation. Nucleic acids encoding the antigens, as well as methods for their production and use are also provided.
    Type: Application
    Filed: June 24, 2010
    Publication date: May 31, 2012
    Applicants: GlaxoSmithKline Biologicals S.A., Biomedical Corporation of Quebec
    Inventors: Normand Blais, Patrick Rheault, Ventzislav B. Vassilev, Virginie Van Scherpenzeel Thim
  • RECOMBINANT RSV VACCINES
    Publication number: 20120093847
    Abstract: This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: June 24, 2010
    Publication date: April 19, 2012
    Inventors: Guy Jean Marie Fernand Pierre Baudoux, Normand Blais, Sonya L. Cyr, Patrick Rheault, Jean-Louis Ruelle
  • CHIMERIC RESPIRATORY SYNCYTIAL VIRUS POLYPEPTIDE ANTIGENS
    Publication number: 20110177117
    Abstract: Chimeric respiratory syncytial virus (RSV) polypeptide antigens are provided. The disclosed polypeptides include a first amino acid sequence comprising an F2 domain uncleavably joined to an F1 domain of a Respiratory Syncytial Virus (RSV) Fusion (F) protein polypeptide; and a second amino acid sequence comprising a portion of an RSV Attachment (G) protein polypeptide comprising an immunologically dominant epitope. The disclosure also provides nucleic acids that encode, and pharmaceutical compositions that contain, the chimeric RSV polypeptides, as well as methods for their production and use.
    Type: Application
    Filed: July 17, 2009
    Publication date: July 21, 2011
    Inventors: Normand Blais, Patrick Rheault
  • Methods for using polypeptides
    Patent number: 7883706
    Abstract: The present invention relates to antigens, more particularly antigens of Streptococcus pyogenes (also called group A streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for prophylaxis, therapy and/or diagnostic.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: February 8, 2011
    Assignee: ID Biomedical Corporation
    Inventors: Denis Martin, Stephane Rioux, Bernard R. Brodeur, Josee Hamel, Patrick Rheault
  • RECOMBINANT RSV ANTIGENS
    Publication number: 20100291147
    Abstract: This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: December 23, 2008
    Publication date: November 18, 2010
    Inventors: Guy Jean Marie Fernand Pierre Baudoux, Normand Blais, Patrick Rheault, Jean-Louis Ruelle
  • CHIMERIC ANTIGENS
    Publication number: 20100203071
    Abstract: Chimeric respiratory syncytial virus (RSV) polypeptide antigens are provided. The disclosed polypeptides include in an N-terminal to C-terminal direction: a first F protein polypeptide domain; a G protein polypeptide domain; and a second F protein polypeptide domain. The disclosure also provides nucleic acids that encode, and pharmaceutical compositions that contain, the chimeric RSV polypeptides, as well as methods for their production and use.
    Type: Application
    Filed: March 20, 2008
    Publication date: August 12, 2010
    Inventors: Norman Blais, David S. Burt, Sonya L. Cyr, Denis L. Martin, Patrick Rheault
  • STREPTOCOCCUS PYOGENES ANTIGENS AND CORRESPONDING DNA FRAGMENTS
    Publication number: 20100119507
    Abstract: The present invention relates to antigens, more particularly antigenS of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.
    Type: Application
    Filed: September 28, 2009
    Publication date: May 13, 2010
    Applicant: ID BIOMEDICAL CORPORATION
    Inventors: Denis Martin, Bernard Brodeur, Josee Hamel, Stephane Rioux, Patrick Rheault
  • antigens and corresponding DNA fragments
    Patent number: 7595057
    Abstract: The present invention relates to antigens, more particularly antigens of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: September 29, 2009
    Assignee: ID Biomedical Corporation
    Inventors: Denis Martin, Bernard Brodeur, Josee Hamel, Stephane Rioux, Patrick Rheault
  • STREPTOCOCCUS PYOGENES POLYPEPTIDES AND CORRESPONDING DNA FRAGMENTS
    Publication number: 20090186820
    Abstract: The present invention relates to antigens, more particularly antigens of Streptococcus pyogenes (also called group A streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for prophylaxis, therapy and/or diagnostic.
    Type: Application
    Filed: January 12, 2009
    Publication date: July 23, 2009
    Applicant: ID BIOMEDICAL CORPORATION
    Inventors: Denis Martin, Stephane Rioux, Bernard R. Brodeur, Josee Hamel, Patrick Rheault